The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 343:1886-1887 December 21, 2000 Number 25
NextNext

The FDA, Regulation, and the Risk of Stroke

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Kernan, W. N.
-Related Article
 by Haller, C. A.
-PubMed Citation
When Jane Henney, commissioner of the Food and Drug Administration (FDA), announced on October 10, 2000, the agency's intention to have products containing phenylpropanolamine withdrawn from the market, another chapter — perhaps the final one — for this over-the-counter drug was opened. The FDA acted even before the results of the work on which the decision is based could be published. In this issue of the Journal, Kernan et al. report the results of an exemplary epidemiologic effort, the Hemorrhagic Stroke Project.1 This project was designed in response to the FDA's concern about the safety of phenylpropanolamine, which began in . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.